Elinzanetant: Australia's second non-hormonal option for hot flushes

What just happened

The TGA registered elinzanetant (Lynkuet) in September 2025, making Australia one of the first countries to approve the drug alongside the US, UK, Canada and Switzerland. The Australian Public Assessment Report (AusPAR) was published in March 2026, confirming the evidence base the regulator reviewed. Elinzanetant is the second non-hormonal treatment of its mechanistic class available in Australia — the first was fezolinetant (Veoza), TGA-approved in March 2024.

For women who have been living with significant hot flushes and cannot use menopausal hormone therapy (MHT), the arrival of a second option with a broader receptor profile matters. Vasomotor symptoms affect around 70% of women going through perimenopause and menopause, and are moderate or severe in roughly one in three of those. The impact on sleep, concentration, work capacity and quality of life is substantial and well-documented. Women who have been told the alternative-to-MHT menu is thin have had that experience confirmed by reality — SSRIs and SNRIs at sub-antidepressant doses, gabapentin, clonidine — none of them developed specifically for this purpose, and none reliably delivering the results MHT achieves.

---

The both-and

Two TGA-registered non-hormonal options now exist. Neither is on the PBS. The underlying science is genuinely new. All three are true simultaneously.

The mechanism is not a repurpose

The breakthrough behind both fezolinetant and elinzanetant is mechanistic, not a repurposing of an older drug class. Hot flushes are not simply “hormonal fluctuation.” The proximate trigger is dysregulated activity in a cluster of hypothalamic neurons — KNDy neurons, named for the three signalling molecules they express: kisspeptin, neurokinin B, and dynorphin. During perimenopause, falling oestrogen levels disinhibit these neurons, leading to overactivity in the thermoregulatory centre of the hypothalamus. This produces the cascade: peripheral vasodilation, sweating, the subjective heat sensation, the disrupted sleep architecture. A 2026 review in Nature Reviews Endocrinology details how this KNDy pathway became the target for the first class of drugs designed specifically for vasomotor symptoms.

Fezolinetant (Veoza) targets the NK3 receptor only. Elinzanetant (Lynkuet) blocks both NK1 and NK3. This dual mechanism appears relevant to the breadth of symptoms elinzanetant addresses — including sleep disturbance associated with perimenopause, where NK1 receptor activity in the brain’s arousal pathways plays a role. The Australian Prescriber review of fezolinetant explains the broader NK3 pharmacology; elinzanetant adds NK1 blockade to that foundation.

The breast cancer dimension is clinically significant

The most important part of the elinzanetant story is what it means for women on breast cancer endocrine therapy. Women with hormone-receptor-positive breast cancer — the most common breast cancer type — are treated with tamoxifen or aromatase inhibitors, sometimes combined with ovarian function suppression. These therapies are effective. They also induce or intensify menopausal symptoms. These women cannot use oestrogen-containing MHT. Until recently, their options were limited to repurposed medicines with modest effect sizes.

EBCC 2026 trial data, presented at the European Breast Cancer Conference, showed elinzanetant reduced hot flush frequency and severity by approximately two-thirds — and this effect held regardless of whether the woman was on tamoxifen, an aromatase inhibitor, or combined with ovarian function suppression. The International Menopause Society reviewed the data in March 2026 and noted the clinical significance for a population who have historically been underserved by their symptom management options.

The access barrier remains

Neither elinzanetant nor fezolinetant is PBS-listed in Australia. Out-of-pocket costs are significant. The path from TGA registration to PBS listing is a separate, often lengthy process. Women who need these medicines now and cannot afford full cost face a real and ongoing barrier. This is the frontier worth watching.

---

2 cents

If you are in perimenopause or menopause with moderate to severe hot flushes and MHT is not suitable or not your preference: two TGA-registered non-hormonal options in this drug class now exist in Australia. Both work at the level of the hypothalamus thermoregulatory pathway — not by providing oestrogen. Both have reasonable phase 3 evidence behind them.

If you are managing hormone-receptor-positive breast cancer on tamoxifen or an aromatase inhibitor and hot flushes are disrupting your sleep or your ability to stay on treatment: the EBCC 2026 data and the existing TGA registration make this a different conversation than it was 18 months ago. This may be worth raising explicitly with your oncologist or your GP — not as a request they may not have heard before, but as a question about a medicine that now has a regulatory status in this country.

Cost remains a real barrier for both drugs. The PBS listing question is worth raising actively — with your prescriber, or via consumer health advocacy channels.

This is general information about TGA-registered medicines. Individual suitability depends on your full clinical history. Costs and PBS status may change; your GP or pharmacist can confirm current access.

---

Verdict

Verdict: yes — worth knowing about.

Elinzanetant expands the non-hormonal treatment menu for women with significant hot flushes, and its efficacy in women on breast cancer endocrine therapy fills a gap that has left a large group of women with inadequate symptom management for too long. PBS listing remains outstanding — that is the access frontier.

---

Sources cited

1. TGA — ARTG listing: LYNKUET elinzanetant 60 mg (September 2025)
2. TGA — AusPAR: Lynkuet elinzanetant (March 2026)
3. ecancer — EBCC 2026: Elinzanetant reduces hot flushes regardless of endocrine therapy type
4. International Menopause Society — Elinzanetant for vasomotor symptoms in women with breast cancer (March 2026)
5. Australian Prescriber — Fezolinetant for moderate to severe vasomotor symptoms
6. Nature Reviews Endocrinology — Risk factors, management and consequences of severe menopausal vasomotor symptoms (2026)